<DOC>
	<DOCNO>NCT01420055</DOCNO>
	<brief_summary>This prospective , open-label , multi-center phase IV study ass response fingolimod initiation accord cop profile adult patient highly active relapse remit multiple sclerosis France .</brief_summary>
	<brief_title>Fingolimod -Response According Coping - Evaluation</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>1865 yearold male &amp; female RRMS ( 2005 revise McDonald criterion ) correspond fingolimod indication ( Europe ) EDSS score 0 5.5 inclusive History immune system chronic disease MS know immunodeficiency syndrome ; increase risk opportunistic infection , include immunocompromised patient ; severe active infection , active chronic infection ; negative varicellazoster virus IgG antibody ; live live attenuate vaccine ; Active malignancy ; Macular edema ; Cardiac disease medicine decrease heart rate ; severe liver impairment ; lymphocyte count &lt; 800/mm3 ; Pregnant nursing ( lactate ) woman /childbearing potential UNLESS use effective contraceptive method ; Hypersensitivity ; participation clinical research study within 6 month prior baseline ; prior participation trial fingolimod Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Multiple sclerosis</keyword>
	<keyword>Fingolimod</keyword>
	<keyword>Coping</keyword>
	<keyword>Anxiety</keyword>
	<keyword>France</keyword>
	<keyword>Treatment Satisfaction Questionnaire Medication-9 item ( TSQM 9 )</keyword>
	<keyword>Active</keyword>
</DOC>